Ligand Pharmaceuticals (LGND) Return on Invested Capital (2011 - 2025)

Ligand Pharmaceuticals (LGND) has 12 years of Return on Invested Capital data on file, last reported at 1.85% in Q3 2025.

• For the quarter ending Q3 2025, Return on Invested Capital rose 668.0% year-over-year to 1.85%; the trailing twelve-month figure through Sep 2025 stood at 1.85% (up 668.0% YoY), and the FY2024 full-year result was 7.31%, up 466.0% from the prior year.
• Return on Invested Capital improved to 1.85% in Q3 2025, from 4.21% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 7.7% in Q1 2022 to a low of 6.97% in Q1 2025.
• A 5-year average of 0.18% and a median of 0.0% in 2023 frame the typical range for Return on Invested Capital.
• Across the five-year window, Return on Invested Capital soared 762 bps in 2022 and sank 770 bps in 2023, its largest moves.
• Tracing LGND's Return on Invested Capital over 5 years: stood at 0.32% in 2021, then slumped by 100 bps to 0.0% in 2022, then jumped by 5822 bps to 0.0% in 2023, then soared by 556389 bps to 7.31% in 2024, then tumbled by 75 bps to 1.85% in 2025.
• Business Quant data shows LGND's Return on Invested Capital at 1.85% in Q3 2025, 4.21% in Q2 2025, and 6.97% in Q1 2025.